Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;134(4):622-629.
doi: 10.1111/bju.16448. Epub 2024 Jul 5.

Primary retroperitoneal lymph node dissection for metastatic non-seminomatous germ cell tumours: outcomes and adjuvant chemotherapy

Ahmad Mousa  1   2 , Lynn Anson-Cartwright  2 , Eshetu G Atenafu  3 , Michael A S Jewett  2 , Philippe Bedard  4 , Di Maria Jiang  4 , Rachel Glicksman  5 , Peter Chung  5 , Padraig Warde  5 , Martin O'Malley  6 , Susan Prendeville  7 , Robert J Hamilton  2
Affiliations

Primary retroperitoneal lymph node dissection for metastatic non-seminomatous germ cell tumours: outcomes and adjuvant chemotherapy

Ahmad Mousa et al. BJU Int. 2024 Oct.

Abstract

Objectives: To compare the outcomes and treatment burden of primary retroperitoneal lymph node dissection (pRPLND) alone versus pRPLND + adjuvant chemotherapy (AC) in patients with pathological stage II (PSII) non-seminomatous germ cell tumours (NSGCT).

Patients and methods: Retrospective review of the Princess Margaret Cancer Center eTestes cancer database identified patients with PSII NSGCT after pRPLND between 1995 and 2020. The primary outcome was relapse-free survival (RFS). Secondary outcomes included disease-specific survival (DSS), burden of relapse treatment, and factors associated with relapse.

Results: A total of 109 PSII patients were included in the study. There were 96 patients treated with pRPLND alone and 13 treated with pRPLND + AC. The median follow-up was 61 months. The 5-year RFS was 72% for the pRPLND-only group vs 92% for the pRPLND + AC group (hazard ratio [HR] 4.372, 95% confidence interval [CI] 0.59-32.36; P = 0.11). Within the pRPLND-only group the 5-year RFS differed by pN stage (pN1 = 94% vs pN2/N3 = 67%, P = 0.03). Despite a higher relapse rate within the pRPLND-only group, the DSS was similar at 5 years (98% pRPLND only vs 100% pRPLND + AC, P = 0.48). Only 24 (25%) of the patients in the pRPLND-only group required any subsequent chemotherapy. Despite achieving similar survival, the cumulative post-RPLND treatment burden was less for the pRPLND-only group than the pRPLND+AC group overall (average 1.23 vs 2.46 cycles of chemotherapy per patient in group).

Conclusion: The majority of patients with PSII NSGCT treated with pRPLND alone do not experience a recurrence or require chemotherapy. Despite a lower relapse risk when AC is given, no difference in survival was seen but higher chemotherapy burden was entertained. AC may constitute overtreatment for most patients with PSII NSGCT treated with pRPLND.

Keywords: adjuvant chemotherapy; non‐seminoma; primary retroperitoneal lymph node dissection; surveillance; testicular cancer.

PubMed Disclaimer

References

    1. National Comprehensive Cancer Network Testicular Cancer Guidelines (Version 1.2023). 2023 Nccnorg. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf. Accessed January 2024
    1. Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem 2019; 88: 102925
    1. Gurjal A, An T, Valdivieso M, Kalemkerian GP. Etoposide‐induced pulmonary toxicity. Lung Cancer 1999; 26: 109–112
    1. Kobayashi K, Ratain MJ. Pharmacodynamics and long‐term toxicity of etoposide. Cancer Chemother Pharmacol 1994; 34(Suppl): S64–S68
    1. Tachibana I, Kern SQ, Douglawi A et al. Primary retroperitoneal lymph node dissection for patients with pathologic stage II nonseminomatous germ cell tumor‐N1, N2, and N3 disease: is adjuvant chemotherapy necessary? J Clin Oncol 2022; 40: 3762–3769

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources